Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid add-on after myocardial infarction for LDL-C target achievement
2022-003526-50Phase 3Active
- Sponsor
- Hannover Medical School
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bempedoic acid in myocardial infarction (MI), acute coronary syndrome (ACS) and hypercholesterolemia, sponsored by Hannover Medical School. Primary endpoint: Achievement of ESC LDL-C target after triple therapy. Started Jan 2023; status: active.
02
Drugs
bempedoic acid
03
Conditions
myocardial infarction (MI)acute coronary syndrome (ACS)hypercholesterolemia
Beyond the preview
Go deeper on 2022-003526-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003526-50.